|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Condyloma acuminatum of the anal canal,treated with endoscopic submucosal dissection显示文摘Condyloma acuminatum(CA) is a common sexually transmitted disease caused by human papilloma virus infection. Not all individuals develop persistent, progressive disease, but careful follow up is required with moderate-to-severe dysplasia to prevent progression to malignancy. Standard therapies include surgical treatments(trans-anal resection and transanal endoscopic microsurgery) and immunotherapeutic and topical methods(topical imiquimod); however, local recurrence remains a considerable problem. Here, we report a case with superficial CA of the anal canal, treated with endoscopic submucosal dissection(ESD). A 28-year-old man presented with a chief complaint of hematochezia. Digital exam did not detect a tumor. Screening colonoscopy revealed 10-mm long, whitish condyles extending from the anal canal to the lower rectum. The lesion covered almost the whole circumference, and only a small amount of normal mucosa remained. Magnifying endoscopy with narrow band imaging showed brownish hairpin-shaped, coiled capillaries. Although histopathological diagnosis by biopsy revealed CA, accurate histological differentiation between CA, papilloma, and squamous cell carcinoma can be difficult with a small specimen. Therefore, weperformed diagnostic ESD, which provides a complete specimen for precise histopathological evaluation. The pathological diagnosis was CA, with moderate dysplasia(anal intraepithelial neoplasia 2). There was no recurrence at 16 mo after the initial ESD. Compared to surgical treatment, endoscopic diagnosis and resection could be performed simultaneously and the tumor margin observed clearly with a magnifying chromocolonoscopy, resulting in less recurrence. These findings suggest that endoscopic resection may be an alternative method for CA that prevents recurrence. | Akiko Sasaki Takeshi Nakajima Hideto Egashira Kotaro Takeda Shinnosuke Tokoro Chikamasa Ichita Sakue Masuda Haruki Uojima Kazuya Koizumi Takeshi Kinbara Taku Sakamoto Yutaka Saito Makoto Kako | 2016 | World Journal of Gastroenterology2016，22，8： | 11 |
| 2 | Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?显示文摘AIM:To investigate the effects of Helicobacter pylori (H pylori)eradication therapy for treatment of peptic ulcer on the incidence of gastric cancer. METHODS:A multicenter prospective cohort study was conducted between November 2000 and December 2007 in Yamagata Prefecture,Japan.The study included patients with H pylori-positive peptic ulcer who decided themselves whether to receive H pylori eradication(eradication group)or conventional antacid therapy(non-eradication group).Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys,as well as Yamagata Prefectural Cancer Registry data,and was compared between the two groups and by results of H pylori therapy.RESULTS:A total of 4133 patients aged between 13 and 91 years(mean 52.9 years)were registered,and 56 cases of gastric cancer were identified over a mean follow-up of 5.6 years.The sex-and age-adjusted incidence ratio of gastric cancer in the eradication group, as compared with the non-eradication group,was 0.58 (95%CI:0.28-1.19)and ratios by follow-up period(<1 year,1-3 years,>3 years)were 1.16(0.27-5.00),0.50 (0.17-1.49),and 0.34(0.09-1.28),respectively.Longer follow-up tended to be associated with better prevention of gastric cancer,although not to a significant extent.No significant difference in incidence of gastric cancer was observed between patients with successful eradication therapy(32/2451 patients,1.31%)and those with treatment failure(11/639 patients,1.72%).Among patients with duodenal ulcer,which is known to be more prevalent in younger individuals,the incidence of gastric cancer was significantly less in those with successful eradication therapy(2/845 patients,0.24%)than in those with treatment failure(3/216 patients,1.39%). CONCLUSION:H pylori eradication therapy for peptic ulcer patients with a mean age of 52.9 years at registration did not significantly decrease the incidence of gastric cancer. | Katsuhiro Mabe Mikako Takahashi Haruhumi Oizumi Hideaki Tsukuma Akiko Shibata Kazutoshi Fukase Toru Matsuda Hiroaki Takeda Sumio Kawata | 2009 | World Journal of Gastroenterology2009，15，34： | 10 |
| 3 | Nationwide epidemiological survey of chronic pancreatitis in Japan显示文摘 | Yingsong Lin Akiko Tamakoshi Seiki Matsuno Kazunori Takeda Tetsuo Hayakawa Motoji Kitagawa Satoru Naruse Takashi Kawamura Kenji Wakai Rie Aoki Masayo Kojima Yoshiyuki Ohno | 2000 | Journal of Gastroenterology2000，，2： | 2 |
| 4 | EFFICACY OF PROCALCITONIN IN THE EARLY DIAGNOSIS OF BACTERIAL INFECTIONS IN A CRITICAL CARE UNIT显示文摘 | Akiko Nakamura Hideo Wada Makoto Ikejiri Tsuyoshi Hatada Hiroyuki Sakurai Yoshiko Matsushima Junji Nishioka Kazuo Maruyama Shuji Isaji Taichi Takeda Tsutomu Nobori | 2009 | Shock2009，，6： | 2 |
| 5 | A Candidate for Cancer Gene Therapy: MIP-lα Gene Transfer to an Adenocarcinoma Cell Line Reduced T\imorigenicity and Induced Protective Immunity in Immunocompetent Mice显示文摘 | Emi Nakashima Akiko Oya Yuri Kubota Naomi Kanada Ryo Matsushita Kazuyoshi Takeda Fujio Ichimura Kouji Kuno Naofumi Mukaida Kunitaka Hirose Isao Nakanishi Toshimitsu Ujiie Kouji Matsushima | 1996 | Pharmaceutical Research1996，，12： | 1 |
| 6 | Limited contribution of Toll‐like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans显示文摘 | Kiwamu Nakamura Kazuya Miyagi Yoshinobu Koguchi Yuki Kinjo Kaori Uezu Takeshi Kinjo Morikazu Akamine Jiro Fujita Ikuo Kawamura Masao Mitsuyama Yoshiyuki Adachi Naohito Ohno Kiyoshi Takeda Shizuo Akira Akiko Miyazato Mitsuo Kaku Kazuyoshi Kawakami | 2006 | FEMS Immunology & Medical Microbiology2006，，： | 1 |
| 7 | Analysis of Expression Patterns of Breast Cancer-Specific Markers (Mammaglobin and Gross Cystic Disease Fluid Protein 15) in Lung and Pleural Tumors显示文摘 | Takeda Yuji Tsuta Koji Shibuki Yasuo Hoshino Tatsuhiro Tochigi Naobumi Maeshima Akiko Miyagi Asamura Hisao Sasajima Yuko Ito Tsuyoshi Matsuno Yoshihiro | 2008 | Archives of Pathology & Laboratory Medicine2008，，2： | 1 |
| 8 | Quantification of 1,3-dimethylol-5,5-dimethylhydantoin and its decomposition pwducts in cosmetics by high-performance liquid chromatography显示文摘 | Akiko Asada Takahiro Doi Akihiro Takeda | 2012 | Journal of Pharmaceutical and Biomedical Analysis2012，6768，： | 1 |
| 9 | Curcumin targets the AKT–mTOR pathway for uterine leiomyosarcoma tumor growth suppression显示文摘 | Tze Fang Wong Takashi Takeda Bin Li Kenji Tsuiji Akiko Kondo Mari Tadakawa Satoru Nagase Nobuo Yaegashi | 2014 | International Journal of Clinical Oncology2014，，2： | 1 |
| 10 | Application of low-viscosity ionic liquid to the electrolyte of double-layer capacitors显示文摘 | Makoto Ue Masaynki Takeda Akiko Toriumi | 2003 | Journal of the Electrochemical Society2003，150，4： | 1 |
| 11 | A Candidate for Cancer Gene Therapy: MIP-lα Gene Transfer to an Adenocarcinoma Cell Line Reduced T\imorigenicity and Induced Protective Immunity in Immunocompetent Mice显示文摘 | Emi Nakashima Akiko Oya Yuri Kubota Naomi Kanada Ryo Matsushita Kazuyoshi Takeda Fujio Ichimura Kouji Kuno Naofumi Mukaida Kunitaka Hirose Isao Nakanishi Toshimitsu Ujiie Kouji Matsushima | 1996 | Pharmaceutical Research1996，，12： | 1 |
| 12 | Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease显示文摘The pathologies associated with age-related brain dysfunction,including Alzheimer's disease(AD),Parkinson's disease,Lewy body dementia,and vascular dementia,often share similarities across multiple diseases.1 While various factors,such as amyloidβ,Tau protein,α-synuclein,chronic inflammation,and impaired cerebral microcirculation have been suggested as potential therapeutic targets,addressing a single factor is unlikely to be sufficient in preventing or treating age-related brain dysfunction.Drawing from these observations. | Akihiko Taguchi Yuka Okinaka Akiko Takeda Takayuki Okamoto Johannes Boltze Carsten Claussen Sheraz Gul | 2023 | Neuroprotection2023，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员